Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation
- 25 November 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 213-219
- https://doi.org/10.1016/j.jcf.2020.11.008
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation Therapeutics
- National Institutes of Health
This publication has 36 references indexed in Scilit:
- Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot studyPediatric Diabetes, 2013
- Change in Sweat Chloride as a Clinical End Point in Cystic Fibrosis Clinical TrialsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sampleQuality of Life Research, 2011
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationThe New England Journal of Medicine, 2010
- Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosisPediatric Pulmonology, 2010
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences of the United States of America, 2009
- Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic FibrosisThe Journal of Pediatrics, 2007